Cellenkos Inc is a clinical-stage biotechnology company based in Houston, TX, specializing in the development of allogeneic, tissue-targeted, immune T-regulatory cell therapies for the treatment of autoimmune diseases and inflammatory disorders.
Their proprietary platform allows for the production of CK0801, a cord blood derived regulatory T cell product that demonstrates superior T cell suppression and anti-inflammatory properties, effectively replacing defective T-REGs and restoring immune homeostasis to control diseases such as lupus, multiple sclerosis, rheumatoid arthritis, Crohn's disease, and aplastic anemia.
Generated from the website